Nuwellis, Inc. (NASDAQ:NUWE – Free Report) – Equities research analysts at Roth Capital dropped their FY2027 earnings per share estimates for shares of Nuwellis in a research note issued on Wednesday, August 28th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $0.30 per share for the year, down from their previous forecast of $0.38. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Nuwellis’ current full-year earnings is ($11.56) per share. Roth Capital also issued estimates for Nuwellis’ FY2028 earnings at $1.82 EPS.
Separately, Roth Mkm reissued a “buy” rating and set a $17.00 price objective on shares of Nuwellis in a research report on Tuesday, August 13th.
Nuwellis Trading Up 5.2 %
NASDAQ NUWE opened at $1.42 on Friday. Nuwellis has a 12 month low of $1.17 and a 12 month high of $92.75. The stock’s fifty day moving average price is $3.21 and its 200-day moving average price is $9.10. The stock has a market cap of $1.96 million, a P/E ratio of 0.00 and a beta of 0.44.
About Nuwellis
Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.
Further Reading
- Five stocks we like better than Nuwellis
- What Investors Need to Know About Upcoming IPOs
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- ETF Screener: Uses and Step-by-Step Guide
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- How to Invest in the Best Canadian Stocks
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.